FDA Requests Entereg Failed Study Data, Adolor Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Alvimopan failed to show statistical significance for the primary endpoint in partner GlaxoSmithKline’s Phase III study. The pending NDA for the postoperative ileus therapy is based on three studies with mixed results.
You may also be interested in...
Entereg Gets Cautious Approval Recommendation; More Safety Data Needed
FDA's Gastrointestinal Drugs Advisory Committee overwhelmingly found that GlaxoSmithKline/ Adolor's Entereg (alvimopan) demonstrates convincing efficacy, leading to a positive recommendation for approval, but the panel also expressed concerns about the limited scope of safety data and an inadequate risk management plan
Entereg Gets Cautious Approval Recommendation; More Safety Data Needed
FDA's Gastrointestinal Drugs Advisory Committee overwhelmingly found that GlaxoSmithKline/ Adolor's Entereg (alvimopan) demonstrates convincing efficacy, leading to a positive recommendation for approval, but the panel also expressed concerns about the limited scope of safety data and an inadequate risk management plan
Adolor's Entereg "Approvable"; Ongoing Study May Provide Confirmatory Data
FDA is requesting that the company confirm efficacy of the postoperative ileus therapy. An ongoing Phase III trial with Entereg could address FDA's concerns.